A Study to Evaluate the Safety, Tolerability, PK, and PD Effects of AZD2389 in Participants With Liver Fibrosis and Compensated Cirrhosis.

Description

The purpose of this study is to measure the safety, tolerability, and the way the body absorbs, distributes, and metabolises AZD2389 as compared to placebo in participants with liver fibrosis and compensated cirrhosis. The study will also examine how the drug acts on the body

Conditions

Liver Fibrosis, Hepatic Cirrhosis

Study Overview

Study Details

Study overview

The purpose of this study is to measure the safety, tolerability, and the way the body absorbs, distributes, and metabolises AZD2389 as compared to placebo in participants with liver fibrosis and compensated cirrhosis. The study will also examine how the drug acts on the body

A Phase 2a, Randomised, Single-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics and Explore the Pharmacodynamic Effects of AZD2389 in Participants With Liver Fibrosis and Compensated Cirrhosis

A Study to Evaluate the Safety, Tolerability, PK, and PD Effects of AZD2389 in Participants With Liver Fibrosis and Compensated Cirrhosis.

Condition
Liver Fibrosis
Intervention / Treatment

-

Contacts and Locations

Chandler

Research Site, Chandler, Arizona, United States, 85224

Rialto

Research Site, Rialto, California, United States, 92377

Atlanta

Research Site, Atlanta, Georgia, United States, 30349

Morehead City

Research Site, Morehead City, North Carolina, United States, 28557

Houston

Research Site, Houston, Texas, United States, 77079

San Antonio

Research Site, San Antonio, Texas, United States, 78215

San Antonio

Research Site, San Antonio, Texas, United States, 78229

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

    Ages Eligible for Study

    18 Years to

    Sexes Eligible for Study

    ALL

    Accepts Healthy Volunteers

    No

    Collaborators and Investigators

    AstraZeneca,

    Study Record Dates

    2025-12-08